Business Wire

Ready, Set, Create: Cricut Unveils Innovations to Double Creativity Speeds

Share

Makers and crafters of the world can now create faster than before with Cricut Explore®3 and Cricut Maker®3. Cricut is the leader in crafting technology that lets people design, create, and personalize with its smart cutting machines. Whether you want to design beautiful decals, brighten up your walls or make personalized t-shirts for your family or friends, Cricut Explore 3 and Cricut Maker 3 cut at a speed of up to eight inches per second. It’s never been quicker or easier to get crafty.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210522005007/en/

“I’m very proud of what our team has accomplished,” said Ashish Arora, CEO at Cricut. “We wanted to take the experience to a whole new level and make sure our next generation of cutting machines make it easier on everyone to create larger projects, more projects, much faster.”

Like the earlier versions of these cutting machines, the Cricut Explore 3 and Cricut Maker 3 lets you get creative with ease using a wide variety of materials including Cricut Smart Materials® (Smart Vinyl, Smart Iron-on, Smart Paper). Creators can also now create cuts of up to 12 feet at once, putting a whole new world of creative possibilities at their fingertips.

Both machines will be available at Cricut.com on 10 June 2021 and at major retailers starting 27 June 2021.

See Your Creativity Skyrocket with Cricut Explore 3

Starting at $299 (MSRP), Cricut Explore 3 cuts over 100 materials, including cardstock, vinyl, iron-on, glitter paper and cork, letting you make an endless array of DIY projects. Delivering quality cutting performance that anyone can use, you can cut, draw, score with this machine, and embellish your projects with flawless text, detailed illustrations, or easy-to-fold creases.

Unleash Your Creativity with Cricut Maker 3

Starting at $399 (MSRP), Cricut Maker 3 is a powerful and versatile machine with the ultimate in cutting performance and versatility. This machine lets you create with more than 300 materials, from the most delicate paper and fabric to tougher materials like leather and balsa wood, all with incredible precision. Cricut Maker 3 features the Adaptive Tool System™ — the only system that intelligently controls the direction of your blade and cut pressure to match the material, and supports the widest range of tools for cutting, scoring, writing, and adding decorative effect, allowing impressive precision when making a variety of projects.

Works with Design Space

Both the Cricut Explore 3 and Cricut Maker 3 are compatible with easy-to-use Design Space software – available on desktop, iOS and Android. Whether you are new to crafting or an experienced maker, Cricut Explore 3 and Cricut Maker 3 let you make DIY magic happen anywhere, any time.

About Cricut Inc.

Cricut Inc. is a creative technology platform company dedicated to encouraging new ways for people to experience making at home. Cricut’s mission is to unleash the creative potential of its users with innovations that bring ideas to life in the form of professional-looking, personalized handmade projects. Cricut’s industry-leading products include its flagship line of smart cutting machines — the Cricut Maker® family, the Cricut Explore® family, and Cricut Joy® — accompanied by other unique tools like Cricut EasyPress®, the Infusible Ink™ system, and a diverse collection of materials. In addition to Cricut’s core offerings, the brand also fosters a thriving community of millions of dedicated users worldwide.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Alexandra Kenway
pr@cricut.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ReNAgade Therapeutics Continues Commitment to GanNA Bio and Glycan Biology27.4.2024 02:09:00 CEST | Press release

ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines,today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the integration of key individuals of GanNA Bio into the ReNAgade ecosystem. GanNA founders Carolyn Bertozzi, Ph.D., and Richard D. Cummings, Ph.D, will now serve as advisors to ReNAgade. “ReNAgade will continue to benefit tremendously from GanNA’s promising work in developing extra-hepatic delivery technology that helps expand the breadth and potential of our own RNA medicines,” said Brian Goodman, Co-founder of ReNAgade. “Delivery is foundational to ReNAgade’s mission to overcome the current limitations of RNA medicines. We believe the technology developed within GanNA will help further solidify ReNAgade’s leadership position as we continue advancing our unique, integrated therapeutic platform.” Formed in 2021 and invested in by ReNAgade, GanNA Bio har

HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY26.4.2024 22:06:00 CEST | Press release

HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2024. The company reported full year revenue of $13.3 billion, up 5.4% YoY. Digital Services revenue grew by 5.3% (CC) and now contributes to 37.3% of IT Services revenue. HCLSoftware’s Annual Recurring Revenue came in at $1.02 billion. During FY24, the company won 73 large deals – 36 in Services and 37 in Software - that translated into TCV (new deal wins) of $9.76 billion, up 10% YoY. For the quarter, revenue came in at $3.43 billion, up 6% YoY. HCLTech won 21 large deals – 13 in Services and eight in Software, with a TCV of $2.29 billion during the quarter. In terms of geographies, Americas was the fastest growing region with 6.8% YoY (CC) growth followed by Europe, which grew by 5.5% YoY (CC). Industry vertical growth was led by Financial Services and Telecommunications, Media, Publishing & Entertainment. While Financial Services grew at 12.1% YoY

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 18:03:00 CEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO ® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 17:43:00 CEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 17:22:00 CEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/Contact information Hawthorn Advisors suzano@hawthornadvisors.com

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye